Market Access

Our mid-sized pharma client was considering in-licensing a new product for chemotherapy-induced diarrhoea.

A mid-sized biotech client sought to develop and validate a payer value proposition for a first-in-class drug indicated for a rare form of dysmorphic short stature.

Our international pharmaceutical company client had two marketed haemophilia products that, although broadly reimbursed across Europe, were subject to frequent pricing and reimbursement discussions with payers.

Our client was the Senior Director of Global Market Access and Pricing of a global mid-size pharmaceutical company who recently acquired a new asset for a metabolic indication. They wanted to explore evidence gaps in the development plan on potential mitigation strategies to optimise price and access outcomes in France, Germany, Italy, Spain, the UK, Nordics, Switzerland, Australia, Canada, China and South Korea.

A major multinational pharma client wanted to prepare for ongoing and future payer engagements for three high-priority legacy products across multiple markets in Europe and Latin America.